We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App





Diasorin Launches LIAISON IQ POC Reader with 10-Minute SARS-CoV-2 Antibody Test

By LabMedica International staff writers
Posted on 22 Apr 2021
Print article
Image: LIAISON IQ POC Reader (Photo courtesy of DiaSorin)
Image: LIAISON IQ POC Reader (Photo courtesy of DiaSorin)
DiaSorin (‎Saluggia‎, Italy) has launched the LIAISON IQ, its new immunodiagnostic Point-of-Care (POC) reader, and the LIAISON QuickDetect COVID TrimericS Ab test, developed with Lumos Diagnostics (Sarasota, FL, USA) in countries accepting the CE Mark.

This first test available on the LIAISON IQ detects specific IgG antibodies against SARS-CoV-2 spike protein in human capillary blood from a finger stick in 10 minutes. In clinical studies, the test showed a specificity of 97.5% and a sensitivity of 98.0%. The test, which utilizes the full-length trimeric form of the SARS-CoV-2 spike protein already in use in the recently launched LIAISON SARS-CoV-2 TrimericS IgG assay, will be an important tool to establish if a patient has had an adaptive immune response to COVID-19 triggered by either a natural infection or by a vaccine.

DiaSorin intends to access this new market starting with a dedicated program in Italy, targeting pharmacies through agreements with distributors to foster capillary placements of the new combined offer of the platform and the antibody assay. Patients will be able to be tested directly in the pharmacies, with a quick time-to-result solution to detect immune response to SARS-CoV-2 with laboratory-setting quality.

The LIAISON IQ and the LIAISON Quick Detect COVID IgG Ab will also be available in the US market following the US Food and Drug Administration (FDA) Authorization. DiaSorin, together with Lumos, is also pursuing the development of a SARS-CoV-2 Antigen test to be CE marked and submitted to US FDA for Emergency Use Authorization (EUA) within Q2 2021.

“The CE Marking of our LIAISON IQ and its first test provide us access to the growing lateral flow business in the Point-of-care market, allowing DiaSorin to follow the decentralization trend of diagnostics,” said Carlo Rosa, CEO of DiaSorin Group. “This is the right timing for entering the immunodiagnostics Point-of-Care business, with a breakthrough lab-quality solution that uses our biological raw materials in a new, nearer-to-patients context. Our decentralized setting IgG test is the perfect solution to check vaccine efficacy, which is a very relevant information in the current context of the pandemic.”

Related Links:
DiaSorin
Lumos Diagnostics


New
Gold Supplier
SARS-COV-2/FLU/RSV RT-PCR Test
SARS-COV-2/FLU/RSV Real Time PCR Kit
New
COVID-19 Antigen Rapid Test
OnSite COVID-19 Ab Rapid Test
New
SARS-CoV-2 S1/S2 IgG Assay
LIAISON SARS-CoV-2 S1/S2 IgG
New
Disposable Sample Saliva Collection Kit
Disposable Sample Saliva Collection Kit

Print article
Mayo Medical Laboratories
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Photograph of the novel capsule-based smell test (Photo courtesy of Queen Mary University of London)

A Novel Capsule-Based Smell Test for Diagnosis of Neurological and Respiratory Diseases

To aid in diagnosing diseases where loss of the sense of smell is a symptom, such as in chronic neurological conditions like Parkinson's and Alzheimer's diseases and in acute respiratory infections such... Read more

Pathology

view channel
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)

Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis

Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion... Read more

Industry

view channel
Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)

Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories

Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.